471 related articles for article (PubMed ID: 32129093)
21. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
Yang JCH; Brose MS; Castro G; Kim ES; Lassen UN; Leyvraz S; Pappo A; López-Ríos F; Reeves JA; Fellous M; Penault-Llorca F; Rudzinski ER; Tabatabai G; Vassal G; Drilon A; Trent J
BMC Cancer; 2022 Jun; 22(1):625. PubMed ID: 35672677
[TBL] [Abstract][Full Text] [Related]
22. Tropomyosin receptor kinase inhibitors in the management of sarcomas.
Wilding CP; Loong HH; Huang PH; Jones RL
Curr Opin Oncol; 2020 Jul; 32(4):307-313. PubMed ID: 32541318
[TBL] [Abstract][Full Text] [Related]
23. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
[TBL] [Abstract][Full Text] [Related]
24. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.
Garrido P; Hladun R; de Álava E; Álvarez R; Bautista F; López-Ríos F; Colomer R; Rojo F
Clin Transl Oncol; 2021 Aug; 23(8):1529-1541. PubMed ID: 33620682
[TBL] [Abstract][Full Text] [Related]
25. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer.
Federman N; McDermott R
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968
[No Abstract] [Full Text] [Related]
26. Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinib.
Laetsch TW
Clin Adv Hematol Oncol; 2024 May; 22 Suppl 3(4):1-11. PubMed ID: 38739704
[No Abstract] [Full Text] [Related]
27. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
Rolfo C; Drilon A; Hong D; McCoach C; Dowlati A; Lin JJ; Russo A; Schram AM; Liu SV; Nieva JJ; Nguyen T; Eshaghian S; Morse M; Gettinger S; Mobayed M; Goldberg S; Araujo-Mino E; Vidula N; Bardia A; Subramanian J; Sashital D; Stinchcombe T; Kiedrowski L; Price K; Gandara DR
Br J Cancer; 2022 Feb; 126(3):514-520. PubMed ID: 34480094
[TBL] [Abstract][Full Text] [Related]
28.
Gambella A; Senetta R; Collemi G; Vallero SG; Monticelli M; Cofano F; Zeppa P; Garbossa D; Pellerino A; Rudà R; Soffietti R; Fagioli F; Papotti M; Cassoni P; Bertero L
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979374
[TBL] [Abstract][Full Text] [Related]
29. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
Hong DS; Bauer TM; Lee JJ; Dowlati A; Brose MS; Farago AF; Taylor M; Shaw AT; Montez S; Meric-Bernstam F; Smith S; Tuch BB; Ebata K; Cruickshank S; Cox MC; Burris HA; Doebele RC
Ann Oncol; 2019 Feb; 30(2):325-331. PubMed ID: 30624546
[TBL] [Abstract][Full Text] [Related]
30. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib.
Kummar S; Berlin J; Mascarenhas L; van Tilburg CM; Geoerger B; Lassen UN; Schilder RJ; Turpin B; Nanda S; Keating K; Childs BH; Chirila C; Laetsch TW; Hyman DM; Drilon A; Hong DS
Curr Probl Cancer; 2021 Dec; 45(6):100734. PubMed ID: 33865615
[TBL] [Abstract][Full Text] [Related]
31. New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions.
Rolfo C; Raez L
Lab Invest; 2017 Nov; 97(11):1268-1270. PubMed ID: 29085074
[TBL] [Abstract][Full Text] [Related]
32. Larotrectinib followed by selitrectinib in a novel
Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P
J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686
[TBL] [Abstract][Full Text] [Related]
33. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
Blauel ER; Laetsch TW
Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
[TBL] [Abstract][Full Text] [Related]
34. Targeting TRK: A fast-tracked application of precision oncology and future directions.
Kojadinovic A; Laderian B; Mundi PS
Crit Rev Oncol Hematol; 2021 Sep; 165():103451. PubMed ID: 34389458
[TBL] [Abstract][Full Text] [Related]
35. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk.
Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ
Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202
[TBL] [Abstract][Full Text] [Related]
36. NTRK point mutations and their functional consequences.
Rogers C; Morrissette JJD; Sussman RT
Cancer Genet; 2022 Apr; 262-263():5-15. PubMed ID: 34972036
[TBL] [Abstract][Full Text] [Related]
37. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.
Lim KHT; Kong HL; Chang KTE; Tan DSW; Tan IBH; Mohamad F; Soh SY; Pang BN; Soo RA; Choo SP; Hsieh WS; Aung L
Asia Pac J Clin Oncol; 2022 Aug; 18(4):394-403. PubMed ID: 34806337
[TBL] [Abstract][Full Text] [Related]
38. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
[TBL] [Abstract][Full Text] [Related]
39. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population.
Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y
J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710
[TBL] [Abstract][Full Text] [Related]
40. Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.
Joshi SK; Qian K; Bisson WH; Watanabe-Smith K; Huang A; Bottomly D; Traer E; Tyner JW; McWeeney SK; Davare MA; Druker BJ; Tognon CE
Blood; 2020 Jun; 135(24):2159-2170. PubMed ID: 32315394
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
